SlideShare une entreprise Scribd logo
1  sur  37
Télécharger pour lire hors ligne
Blinded Adaptations,  
Permutation Tests & T‐Tests
Michael Proschan (NIAID)Michael Proschan (NIAID)
IntroductionIntroduction
• Joint work with Ekkehard Glimm and MartinJoint work with Ekkehard Glimm and Martin 
Posch 2014, Stat. in Med. online 
• See also Posch & Proschan 2012, Stat. in Med. 
31 4146 415331, 4146‐4153
IntroductionIntroduction
• Clinical trials are pre‐meditated!Clinical trials are pre meditated!
• We pre‐specify everything
S i it / i f i it– Superiority/noninferiority
– Population (inclusion/exclusion criteria)
– Primary endpoint
– Secondary endpoints
– Analysis methods
– Sample size/power
IntroductionIntroduction
• Changes made after seeing data are rightlyChanges made after seeing data are rightly 
questioned: are investigators trying to get an 
unfair advantage?
– Changing primary endpoint because another 
endpoint has a bigger treatment effect
– Increasing sample size because the p‐value is close
– Changing primary analysis because “assumptions 
are violated”are violated
– Changing population because of promising 
subgroup resultssubgroup results
IntroductionIntroduction
• What’s the harm? 0 05 is arbitrary anywayWhat s the harm?  0.05 is arbitrary anyway
• Problem: if unlimited freedom to change 
anything the real error rate could be hugeanything, the real error rate could be huge
• Reminiscent of Bible code controversy
– Clairvoyant messages such as “Bin Laden” and 
“twin towers” by skipping letters in Old Testament
– Similar messages can be found by skipping letters 
in any large book (Brendan McKay)
IntroductionIntroduction
• But changes made before unblinding areBut changes made before unblinding are 
different
• Under strong null hypothesis that treatment• Under strong null hypothesis that treatment 
has NO effect, blinded data give no info about 
treatment effecttreatment effect
– Impossible to cheat even if it seems like cheating
E if bli d d d t h bi d l di t ib ti it• E.g., even if blinded data show bimodal distribution, it 
is not caused by treatment if strong null is true 
Permutation TestsPermutation Tests
• Permutation tests condition on all data otherPermutation tests condition on all data other 
than treatment labels
• Under strong null (D Z ) are independent• Under strong null, (D,Z ) are independent, 
where Z are ±1 treatment indicators & D are 
datadata 
– Observed data D would have been observed 
regardless of the treatment givenregardless of the treatment given
– It is as if we observed D FIRST, then made the 
treatment assignments Ztreatment assignments Z
Permutation TestsPermutation Tests
• Peaking at data changes nothing becausePeaking at data changes nothing because 
permutation tests already condition on D
• Conditional distribution of test statistic T(Z Y)• Conditional distribution of test statistic T(Z,Y) 
given D is that of T(Z,y) where y is fixed
Di ib i f Z d d d i i• Distribution of Z depends on randomization 
method 
– Simple
– Permuted block, etc.
Permutation TestsPermutation Tests
T T C C C T C T C C T T C T T C
4 8 4 0 1 3 0 4 4 0 2 5 0 2 1 0
T-C T-C T-C T-C
O ll T C
4.0 3.0 1.5 1.5
Overall T-C
2.5
Permutation TestsPermutation Tests
T C C T C T C T T T C C C T C T
4 8 4 0 1 3 0 4 4 0 2 5 0 2 1 0
T-C T-C T-C T-C
O ll T C
-4.0 3.0 -1.5 0.5
Overall T-C
-0.5
Rerandomization Distribution
Permutation Distribution
100
y
80
Frequency
06004002
11
T-C Mean
-3 -2 -1 0 1 2 3
Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures
• Blinded 2‐stage adaptive procedures use 1stBlinded 2 stage adaptive procedures use 1st  
stage to make design changes
– Sample size (Gould, 1992, Stat. in Med. 11, 55‐66; p ( , , , ;
Gould & Shih, 1992 Commun. in Stat. 21, 2833‐
2853) 
P i d i ( di li li– Primary endpoint (e.g., diastolic versus systolic 
blood pressure)
• Previous argument shows that if adaptation is• Previous argument shows that if adaptation is 
made before unblinding, a permutation test 
on 1st stage data is still validon 1st stage data is still valid
Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures
• Careful! Subtle errors are possibleCareful!  Subtle errors are possible
• E.g., in adaptive regression, which of the 
following is (are) valid?following is (are) valid?
1. From ANCOVAs Y=β01+βz+βixi, i=1,…,k, pick xi
that minimizes MSE; do permutation test onthat minimizes MSE; do permutation test on 
winner
2 From ANCOVAs Y=β 1+β x i=1 k pick x that2. From ANCOVAs Y=β01+βixi, i=1,…,k, pick xi that 
minimizes MSE; do permutation test on 
Y=β01+βz+β*x*, where x* is winnerβ0 β β ,
Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures
• Careful! Subtle errors are possibleCareful!  Subtle errors are possible
• E.g., in adaptive regression, which of the 
following is (are) valid?following is (are) valid?
1. From ANCOVAs Y=β01+βz+βixi, i=1,…,k, pick xi
that minimizes MSE; do permutation test onthat minimizes MSE; do permutation test on 
winner
2 From ANCOVAs Y=β 1+β x i=1 k pick x that2. From ANCOVAs Y=β01+βixi, i=1,…,k, pick xi that 
minimizes MSE; do permutation test on 
Y=β01+βz+β*x*, where x* is winnerβ0 β β ,
Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures
• Unblinding and apparent α‐inflation also possible U b d g a d appa e t α at o a so poss b e
if strong null is false
• E.g., change primary endpoint based on “blinded” g g p y p
data (X,Y1,Y2), Y1 and Y2 are potential primaries 
and X=level of study drug in blood
– X completely unblinds
– Can then pick Y1 or Y2 with biggest z‐score
Clearly inflates α– Clearly inflates α
– Problem: strong null requires no effect on ANY
variable examined (including X=level of study drug)
Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures
• Claim: the following procedure is validClaim: the following procedure is valid
– After viewing 1st stage data D1, choose test 
statistic T1(Y1 Z1) and second stage data to collectstatistic T1(Y1,Z1) and second stage data to collect
– After observing D2, choose T2(Y2,Z2) and method 
of combining T1 and T2, f(T1,T2)of combining T1 and T2, f(T1,T2)
– Conditional distribution of f(T1,T2) given (D1,D2) is 
its stratified permutation distributionp
– Stratified permutation test controls conditional, & 
therefore unconditional type I error rate 
Focus of Rest of TalkFocus of Rest of Talk
• Permutation tests are asymptoticallyPermutation tests are asymptotically 
equivalent to t‐tests
• Suggests that adaptive t tests might be valid if• Suggests that adaptive t‐tests might be valid if 
adaptive permutation tests are
W id i b• We consider connections between 
permutation and t‐tests, and validity of 
d i f d i iadaptive t‐tests from adaptive permutation 
tests 
One‐Sample CaseOne Sample Case
• Community randomized trials sometimes pair Co u ty a do ed t a s so et es pa
match & randomize within pairs
• E.g., COMMIT trial used community intervention g y
to help people quit smoking—11 matched pairs
• D=difference in quit rates between treatment (T) 
& control (C)
T C           D=T‐C
Pair i         0.30     0.25        +0.05
One‐Sample CaseOne Sample Case
• Community randomized trials sometimes pair Co u ty a do ed t a s so et es pa
match & randomize within pairs
• E.g., COMMIT trial used community intervention g y
to help people quit smoking—11 matched pairs
• D=difference in quit rates between treatment (T) 
& control (C)
C T  D=T‐C
Pair i         0.30     0.25        ‐0.05
One‐Sample CaseOne Sample Case
• Permuting labels changes only sign of DPermuting labels changes only sign of D
• Permutation test conditions on |Di|= di
+; 
d + d d + ll lik l‐di
+ and di
+ are equally likely
• The permutation distribution of Di is dist. ofThe permutation distribution of Di is dist. of
21w p1where /ZdZ  
21w.p.1
21w.p.1where,
/
/ZdZ iii


One‐Sample CaseOne Sample Case
• In 1st stage, adapt based on |D1|,…,|Dn| (blinded)g , p | 1|, ,| n| ( )
– E.g., increase stage 2  sample size because |Di| is very 
large
• What is conditional distribution of 1st stage sum• What is conditional distribution of  1st stage sum 
ΣDi given |D1|=d1
+,…,|Dn|= dn
+ and the 
adaptation?adaptation?
– The adaptation is a function of |D1|,…,|Dn| 
– The null distribution of ΣDi given |D1|=d1
+,…,|Dn|= dn
+
i g | 1| 1 , ,| n| n
IS its permutation distribution
– Conclusion: permutation test on stage 1 data still valid
One‐Sample CaseOne Sample Case
• Mean and variance of permutationMean and variance of permutation 
distribution are
    
0)(E iiii ZEddZ 
  

 222
)(var
)(
iiiii
iiii
dZEddZ
One‐Sample CaseOne Sample Case
• Asymptotically, permutation distribution is sy ptot ca y, pe utat o d st but o s
normal with this mean and variance (Lindeberg‐
Feller CLT)
• I.e., conditional distribution of Di given , i g
|D1|=d1
+,…,|Dn|= dn
+ is asymptotically N(0,di
2)
• Depends on |D1|=d1
+,…,|Dn|= dn
+ only through 
L2=di
2L di
One‐Sample CaseOne Sample Case
• Asymptotically, permutation distribution ofAsymptotically, permutation distribution of 
  N
d
dN
D
D
T ii
2
2
2
)1,0(
,0
' 




LD
dD ii
2


n
L
Dns
ns
D
T i
i
2
22
02
0
)/1(;'  
• Like t‐test with variance estimate s0
2 instead 
of usual sample variance s2
One‐Sample CaseOne Sample Case
• Recap: Permutation distribution of T’ is dist ofRecap: Permutation distribution of T is dist of 

 12
|||,...,|given' n
i
DD
D
D
T


2
i'
i
DT
D
 

22
2
d dtd ')10(
given' i
DLN
DT
• Conclusion: T’ is asymptotically indep of L2
  22
ondependtdoesn')1,0( iDLN
One‐Sample CaseOne Sample Case
• Begs question, is this true for all sample sizesBegs question, is this true for all sample sizes 
under normality assumption?
• if Di are iid N(0,2), then canif Di are iid N(0, ), then can
?fti d db' 2
 i
D
D
T ?oftindependenbe' 2
2 

 i
i
i
D
D
T
• Seems crazy, but it’s true!
One‐Sample CaseOne Sample Case
• One way to see that T’ is independent of Di
2One way to see that T is independent of Di
uses Basu’s theorem: 
• Recall S is sufficient for θ if F(y|s) does not 
d d θ i i l if { ( )} f ll θdepend on θ; it is complete if E{g(S)}=0 for all θ
implies g(S)≡0 with probability 1
• A is ancillary if its distribution does not depend• A is ancillary if its distribution does not depend 
on θ
• Basu, 1955, Sankhya 15, 377‐380:
If S is a complete, sufficient statistic and A 
is ancillary, then S and A are independent
One‐Sample CaseOne Sample Case
• Consider Di iid N(0 2) with 2 unknownConsider Di iid N(0, ) with  unknown
–Di
2 is complete and sufficient
– T’= Di/(Di
2)1/2 is ancillary because it is scale‐
invariant
– By Basu’s theorem, T’ and Di
2 are independent
One‐Sample CaseOne Sample Case
• Same argument shows that the usual t‐Same argument shows that the usual t
statistic is independent of Di
2
2 2• Under Di iid N(0,2) with 2 unknown
–Di
2 is complete and sufficient
– Usual t‐statistic T= Di/(ns2)1/2 is ancillary
– By Basu’s theorem T and D 2 are independent– By Basu s theorem, T and Di are independent 
( Shao (2003): Mathematical Statistics, Springer) 
One‐Sample CaseOne Sample Case
• This result is important for adaptive sample sizeThis result is important for adaptive sample size 
calculations
– Stage 1 with n1= half of original sample size: changeStage 1 with n1  half of original sample size: change 
second stage sample size to n2=n2(ΣDi
2)
– Conditioned on ΣD 2:– Conditioned on ΣDi : 
• Test statistic T1 has exact t‐distribution with n1‐1 d.f.
• Test statistic T2 has exact t‐distribution with n2‐1 d.f. and is 2 2
independent of T1
• P‐values P1 and P2 are independent U(0,1)
• Y={n 1/2Φ‐1(P )+n 1/2Φ‐1(P )}/(n +n )1/2 is N(0 1) under H• Y={n1
1/2Φ 1(P1)+n2
1/2Φ 1(P2)}/(n1+n2)1/2 is N(0,1) under H0
One‐Sample CaseOne Sample Case
• Reject if Y>zReject if Y>zα
• Conditioned on ΣDi
2, type I error rate is α
• Unconditional type I error rate is α as well
• Most other two‐stage procedures are onlyMost other two stage procedures are only 
approximate
One‐Sample CaseOne Sample Case
• Could even make other adaptations like changing p g g
primary endpoint
• Look at ΣDi
2 for each endpoint and determine 
which one is primary  
 2– E.g., pick endpoint with smallest Di
2
• Slight generalization of our result shows that• Slight generalization of our result shows that 
conditional distribution of T given adaptation is 
still exact t 
One‐Sample CaseOne Sample Case
• Shows that conditional type I error rate givenShows that conditional type I error rate given 
adaptation is controlled at level α
• Unconditional type I error rate must also be• Unconditional type I error rate must also be 
controlled at level α
D i i l i i li• Derivation assumes multivariate normality 
with variance/covariance not depending on 
mean
Two‐Sample CaseTwo Sample Case
• Can use same reasoning in 2‐sample setting Ca use sa e easo g sa p e sett g
• With equal sample sizes, the numerator is
 YZYY
• Permutation distribution is distribution of
  ii
C
i
T
i YZYY
Permutation distribution is distribution of 
  0,1each, iiii ZZyZ
• Let sL
2 be “lumped” variance of all data 
(treatment and control)(treatment and control) 
Two‐Sample CaseTwo Sample Case
• Mean and variance of permutation distribution p
are
  0)(EE iiii ZyyZ  
  22
)(
1
1
var Lii syy
n
yZ 






 
• Basu’s theorem shows usual 2‐sample T is 
independent of sL
2 under null hypothesis ofindependent of sL under null hypothesis of 
common mean
• Conditional distribution of T given sL
2 is still t
Two‐Sample CaseTwo Sample Case
• Two‐stage procedureTwo stage procedure
– Stage 1: look at lumped variance and change stage 
2 sample size
– Conditioned on 1st stage lumped variance & H0
• T1 has t‐distribution with n1‐2 d.f.
• T2 has t‐distribution with n2‐2 d.f. & independent of T1
• P‐values P1 and P2 are independent uniforms
• {n1
1/2Φ‐1(P1)+n2
1/2Φ‐1(P2)}/(n1+n2)1/2 is N(0 1) under H0{n1 Φ (P1)+n2 Φ (P2)}/(n1+n2) is N(0,1) under H0
– Controls type I error rate conditionally and 
unconditionally
SummarySummary
• Permutation tests are often valid even inPermutation tests are often valid even in 
adaptive settings if blind is maintained
• There is a close connection between• There is a close connection between 
permutation tests and t‐tests
C d d lidi f d i f• Can deduce validity of adaptive t‐tests from 
validity of adaptive permutation tests

Contenu connexe

Tendances

Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related  Quality-of-life AssessmentRobust Methods for Health-related  Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
dylanturner22
 
Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life AssessmentRobust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
dylanturner22
 
2010 smg training_cardiff_day1_session3_higgins
2010 smg training_cardiff_day1_session3_higgins2010 smg training_cardiff_day1_session3_higgins
2010 smg training_cardiff_day1_session3_higgins
rgveroniki
 

Tendances (9)

2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
 
Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related  Quality-of-life AssessmentRobust Methods for Health-related  Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
 
Sample size for phase ii clinical trials-Simons design and mcp mod case studies
Sample size for phase ii clinical trials-Simons design and mcp mod case studies Sample size for phase ii clinical trials-Simons design and mcp mod case studies
Sample size for phase ii clinical trials-Simons design and mcp mod case studies
 
Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life AssessmentRobust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
 
Measures and feedback 2016
Measures and feedback 2016Measures and feedback 2016
Measures and feedback 2016
 
2010 smg training_cardiff_day1_session3_higgins
2010 smg training_cardiff_day1_session3_higgins2010 smg training_cardiff_day1_session3_higgins
2010 smg training_cardiff_day1_session3_higgins
 
Innovative sample size methods for adaptive clinical trials webinar web ver...
Innovative sample size methods for adaptive clinical trials webinar   web ver...Innovative sample size methods for adaptive clinical trials webinar   web ver...
Innovative sample size methods for adaptive clinical trials webinar web ver...
 
Ct lecture 8. comparing two groups categorical data
Ct lecture 8. comparing two groups   categorical dataCt lecture 8. comparing two groups   categorical data
Ct lecture 8. comparing two groups categorical data
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug Products
 

En vedette

Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...
Cytel USA
 
EUGM 2011 | JEHL | group sequential designs with 2 time to event endpoints
EUGM 2011 | JEHL | group sequential designs with 2 time to event endpointsEUGM 2011 | JEHL | group sequential designs with 2 time to event endpoints
EUGM 2011 | JEHL | group sequential designs with 2 time to event endpoints
Cytel USA
 
Eugm 2012 gaydos - design and analysis approaches to evaluate cardiovascula...
Eugm 2012   gaydos - design and analysis approaches to evaluate cardiovascula...Eugm 2012   gaydos - design and analysis approaches to evaluate cardiovascula...
Eugm 2012 gaydos - design and analysis approaches to evaluate cardiovascula...
Cytel USA
 
Báo cáo thực tập - Lần 1 - Hoàng Thanh Quý
Báo cáo thực tập - Lần 1 - Hoàng Thanh QuýBáo cáo thực tập - Lần 1 - Hoàng Thanh Quý
Báo cáo thực tập - Lần 1 - Hoàng Thanh Quý
Quý Đồng Nast
 
Tổng kết Báo cáo thực tập Athena - Hoàng Thanh Quý
Tổng kết Báo cáo thực tập Athena - Hoàng Thanh QuýTổng kết Báo cáo thực tập Athena - Hoàng Thanh Quý
Tổng kết Báo cáo thực tập Athena - Hoàng Thanh Quý
Quý Đồng Nast
 
How to select an Engine Hoist
How to select an Engine HoistHow to select an Engine Hoist
How to select an Engine Hoist
Brad Evans
 

En vedette (12)

2014 EUGM - Blinded Adaptations, Permutations Tests and T Tests
2014 EUGM - Blinded Adaptations, Permutations Tests and T Tests2014 EUGM - Blinded Adaptations, Permutations Tests and T Tests
2014 EUGM - Blinded Adaptations, Permutations Tests and T Tests
 
Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...
 
EUGM 2011 | JEHL | group sequential designs with 2 time to event endpoints
EUGM 2011 | JEHL | group sequential designs with 2 time to event endpointsEUGM 2011 | JEHL | group sequential designs with 2 time to event endpoints
EUGM 2011 | JEHL | group sequential designs with 2 time to event endpoints
 
Báo cáo tổng kết thực tập athena
Báo cáo tổng kết thực tập athenaBáo cáo tổng kết thực tập athena
Báo cáo tổng kết thực tập athena
 
Eugm 2012 gaydos - design and analysis approaches to evaluate cardiovascula...
Eugm 2012   gaydos - design and analysis approaches to evaluate cardiovascula...Eugm 2012   gaydos - design and analysis approaches to evaluate cardiovascula...
Eugm 2012 gaydos - design and analysis approaches to evaluate cardiovascula...
 
Báo cáo thực tập - Lần 1 - Hoàng Thanh Quý
Báo cáo thực tập - Lần 1 - Hoàng Thanh QuýBáo cáo thực tập - Lần 1 - Hoàng Thanh Quý
Báo cáo thực tập - Lần 1 - Hoàng Thanh Quý
 
Tổng kết Báo cáo thực tập Athena - Hoàng Thanh Quý
Tổng kết Báo cáo thực tập Athena - Hoàng Thanh QuýTổng kết Báo cáo thực tập Athena - Hoàng Thanh Quý
Tổng kết Báo cáo thực tập Athena - Hoàng Thanh Quý
 
BRAND NURTURING
BRAND NURTURINGBRAND NURTURING
BRAND NURTURING
 
How to select an Engine Hoist
How to select an Engine HoistHow to select an Engine Hoist
How to select an Engine Hoist
 
Campionato mondiale di calcio 2014
Campionato mondiale di calcio 2014Campionato mondiale di calcio 2014
Campionato mondiale di calcio 2014
 
Sistema dei commenti conciliante
Sistema dei commenti concilianteSistema dei commenti conciliante
Sistema dei commenti conciliante
 
A Bayesian Industry Approach to Phase 1 Combination Trials in Oncology
A Bayesian Industry Approach to Phase 1 Combination Trials in OncologyA Bayesian Industry Approach to Phase 1 Combination Trials in Oncology
A Bayesian Industry Approach to Phase 1 Combination Trials in Oncology
 

Similaire à 2014-10-22 EUGM | PROSCHAN | Blinded Adaptations Permutations Tests and T-Tests

Intro to tests of significance qualitative
Intro to tests of significance qualitativeIntro to tests of significance qualitative
Intro to tests of significance qualitative
Pandurangi Raghavendra
 
T test for two independent samples and induction
T test for two independent samples and inductionT test for two independent samples and induction
T test for two independent samples and induction
Emmanuel Buah
 
A05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat TestsA05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat Tests
Leanleaders.org
 
A05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat TestsA05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat Tests
Leanleaders.org
 
Monitoring response variables 13Feb2014
Monitoring response variables 13Feb2014Monitoring response variables 13Feb2014
Monitoring response variables 13Feb2014
Thira Woratanarat
 

Similaire à 2014-10-22 EUGM | PROSCHAN | Blinded Adaptations Permutations Tests and T-Tests (20)

Statistics
StatisticsStatistics
Statistics
 
Intro to tests of significance qualitative
Intro to tests of significance qualitativeIntro to tests of significance qualitative
Intro to tests of significance qualitative
 
Sample determinants and size
Sample determinants and sizeSample determinants and size
Sample determinants and size
 
T test for two independent samples and induction
T test for two independent samples and inductionT test for two independent samples and induction
T test for two independent samples and induction
 
slides Testing of hypothesis.pptx
slides Testing  of  hypothesis.pptxslides Testing  of  hypothesis.pptx
slides Testing of hypothesis.pptx
 
t-test
t-test t-test
t-test
 
Crash Course in A/B testing
Crash Course in A/B testingCrash Course in A/B testing
Crash Course in A/B testing
 
Randomized trials ii dr.wah
Randomized trials ii dr.wahRandomized trials ii dr.wah
Randomized trials ii dr.wah
 
Student's T-Test
Student's T-TestStudent's T-Test
Student's T-Test
 
Chemometrics-ANALYTICAL DATA SIGNIFICANCE TESTS.pptx
Chemometrics-ANALYTICAL DATA SIGNIFICANCE TESTS.pptxChemometrics-ANALYTICAL DATA SIGNIFICANCE TESTS.pptx
Chemometrics-ANALYTICAL DATA SIGNIFICANCE TESTS.pptx
 
Sample size calculation
Sample size calculationSample size calculation
Sample size calculation
 
An introduction to the stepped wedge cluster randomised trial
An introduction to the stepped wedge cluster randomised trial An introduction to the stepped wedge cluster randomised trial
An introduction to the stepped wedge cluster randomised trial
 
A05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat TestsA05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat Tests
 
A05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat TestsA05 Continuous One Variable Stat Tests
A05 Continuous One Variable Stat Tests
 
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptxThe Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
 
Parametric Tolerance Interval Testing
Parametric Tolerance Interval TestingParametric Tolerance Interval Testing
Parametric Tolerance Interval Testing
 
Monitoring response variables 13Feb2014
Monitoring response variables 13Feb2014Monitoring response variables 13Feb2014
Monitoring response variables 13Feb2014
 
Parametric test
Parametric testParametric test
Parametric test
 
Overview of statistics: Statistical testing (Part I)
Overview of statistics: Statistical testing (Part I)Overview of statistics: Statistical testing (Part I)
Overview of statistics: Statistical testing (Part I)
 
Test of significance
Test of significanceTest of significance
Test of significance
 

Plus de Cytel USA

From the clinic to the cfo adaptive trials and financial decision making
From the clinic to the cfo   adaptive trials and financial decision makingFrom the clinic to the cfo   adaptive trials and financial decision making
From the clinic to the cfo adaptive trials and financial decision making
Cytel USA
 
Eugm 2012 pritchett - application of adaptive sample size re-estimation in ...
Eugm 2012   pritchett - application of adaptive sample size re-estimation in ...Eugm 2012   pritchett - application of adaptive sample size re-estimation in ...
Eugm 2012 pritchett - application of adaptive sample size re-estimation in ...
Cytel USA
 
Eugm 2012 oneill - perspective on the current environment for adaptive clin...
Eugm 2012   oneill - perspective on the current environment for adaptive clin...Eugm 2012   oneill - perspective on the current environment for adaptive clin...
Eugm 2012 oneill - perspective on the current environment for adaptive clin...
Cytel USA
 
Eugm 2012 mehta - future plans for east - 2012 eugm
Eugm 2012   mehta - future plans for east - 2012 eugmEugm 2012   mehta - future plans for east - 2012 eugm
Eugm 2012 mehta - future plans for east - 2012 eugm
Cytel USA
 
Eugm 2012 jemiai - introduction to east architect
Eugm 2012   jemiai - introduction to east architectEugm 2012   jemiai - introduction to east architect
Eugm 2012 jemiai - introduction to east architect
Cytel USA
 
Eugm 2012 demets - clinical trials and the impact of regulations
Eugm 2012   demets - clinical trials and the impact of regulationsEugm 2012   demets - clinical trials and the impact of regulations
Eugm 2012 demets - clinical trials and the impact of regulations
Cytel USA
 
Eugm 2011 pocock - dm cs-and-adaptive-trials
Eugm 2011   pocock - dm cs-and-adaptive-trialsEugm 2011   pocock - dm cs-and-adaptive-trials
Eugm 2011 pocock - dm cs-and-adaptive-trials
Cytel USA
 
Eugm 2011 mehta - execution of adaptive trials operational considerations
Eugm 2011   mehta - execution of adaptive trials operational considerationsEugm 2011   mehta - execution of adaptive trials operational considerations
Eugm 2011 mehta - execution of adaptive trials operational considerations
Cytel USA
 
Eugm 2011 mehta - adaptive designs for phase 3 oncology trials
Eugm 2011   mehta - adaptive designs for phase 3 oncology trialsEugm 2011   mehta - adaptive designs for phase 3 oncology trials
Eugm 2011 mehta - adaptive designs for phase 3 oncology trials
Cytel USA
 
EUGM 2011| Fretault | Use of bayesian approach in phase ii
EUGM 2011| Fretault | Use of bayesian approach in phase iiEUGM 2011| Fretault | Use of bayesian approach in phase ii
EUGM 2011| Fretault | Use of bayesian approach in phase ii
Cytel USA
 
EUGM 2011 | DAY | Experiences with interim analyses and dm cs
EUGM 2011 | DAY | Experiences with interim analyses and dm csEUGM 2011 | DAY | Experiences with interim analyses and dm cs
EUGM 2011 | DAY | Experiences with interim analyses and dm cs
Cytel USA
 
EUGM 2011 | DARCHY | Deployment & use of east within sanofi r & d
EUGM 2011 | DARCHY | Deployment & use of east within sanofi r & dEUGM 2011 | DARCHY | Deployment & use of east within sanofi r & d
EUGM 2011 | DARCHY | Deployment & use of east within sanofi r & d
Cytel USA
 

Plus de Cytel USA (20)

From the clinic to the cfo adaptive trials and financial decision making
From the clinic to the cfo   adaptive trials and financial decision makingFrom the clinic to the cfo   adaptive trials and financial decision making
From the clinic to the cfo adaptive trials and financial decision making
 
Eugm 2012 pritchett - application of adaptive sample size re-estimation in ...
Eugm 2012   pritchett - application of adaptive sample size re-estimation in ...Eugm 2012   pritchett - application of adaptive sample size re-estimation in ...
Eugm 2012 pritchett - application of adaptive sample size re-estimation in ...
 
Eugm 2012 oneill - perspective on the current environment for adaptive clin...
Eugm 2012   oneill - perspective on the current environment for adaptive clin...Eugm 2012   oneill - perspective on the current environment for adaptive clin...
Eugm 2012 oneill - perspective on the current environment for adaptive clin...
 
Eugm 2012 mehta - future plans for east - 2012 eugm
Eugm 2012   mehta - future plans for east - 2012 eugmEugm 2012   mehta - future plans for east - 2012 eugm
Eugm 2012 mehta - future plans for east - 2012 eugm
 
Eugm 2012 jemiai - introduction to east architect
Eugm 2012   jemiai - introduction to east architectEugm 2012   jemiai - introduction to east architect
Eugm 2012 jemiai - introduction to east architect
 
Eugm 2012 demets - clinical trials and the impact of regulations
Eugm 2012   demets - clinical trials and the impact of regulationsEugm 2012   demets - clinical trials and the impact of regulations
Eugm 2012 demets - clinical trials and the impact of regulations
 
Eugm 2011 pocock - dm cs-and-adaptive-trials
Eugm 2011   pocock - dm cs-and-adaptive-trialsEugm 2011   pocock - dm cs-and-adaptive-trials
Eugm 2011 pocock - dm cs-and-adaptive-trials
 
Eugm 2011 mehta - execution of adaptive trials operational considerations
Eugm 2011   mehta - execution of adaptive trials operational considerationsEugm 2011   mehta - execution of adaptive trials operational considerations
Eugm 2011 mehta - execution of adaptive trials operational considerations
 
Eugm 2011 mehta - adaptive designs for phase 3 oncology trials
Eugm 2011   mehta - adaptive designs for phase 3 oncology trialsEugm 2011   mehta - adaptive designs for phase 3 oncology trials
Eugm 2011 mehta - adaptive designs for phase 3 oncology trials
 
EUGM 2011 | JEMIAI
EUGM 2011 | JEMIAIEUGM 2011 | JEMIAI
EUGM 2011 | JEMIAI
 
EUGM 2011| Fretault | Use of bayesian approach in phase ii
EUGM 2011| Fretault | Use of bayesian approach in phase iiEUGM 2011| Fretault | Use of bayesian approach in phase ii
EUGM 2011| Fretault | Use of bayesian approach in phase ii
 
EUGM 2011 | DAY | Experiences with interim analyses and dm cs
EUGM 2011 | DAY | Experiences with interim analyses and dm csEUGM 2011 | DAY | Experiences with interim analyses and dm cs
EUGM 2011 | DAY | Experiences with interim analyses and dm cs
 
EUGM 2011 | DARCHY | Deployment & use of east within sanofi r & d
EUGM 2011 | DARCHY | Deployment & use of east within sanofi r & dEUGM 2011 | DARCHY | Deployment & use of east within sanofi r & d
EUGM 2011 | DARCHY | Deployment & use of east within sanofi r & d
 
EUGM 2014 | BEKELE | Adaptive Dose Finding Using Toxicity Probability Intervals
EUGM 2014 | BEKELE | Adaptive Dose Finding Using Toxicity Probability IntervalsEUGM 2014 | BEKELE | Adaptive Dose Finding Using Toxicity Probability Intervals
EUGM 2014 | BEKELE | Adaptive Dose Finding Using Toxicity Probability Intervals
 
EUGM 2014 | BOLOGNESE | Case Studies of Phase 2 Adaptive Dose-Finding Trials
EUGM 2014 | BOLOGNESE | Case Studies of Phase 2 Adaptive Dose-Finding TrialsEUGM 2014 | BOLOGNESE | Case Studies of Phase 2 Adaptive Dose-Finding Trials
EUGM 2014 | BOLOGNESE | Case Studies of Phase 2 Adaptive Dose-Finding Trials
 
2012-05-30 EUGM | GAYDOS | Design & Analysis Approaches to Evaluate Cardiovas...
2012-05-30 EUGM | GAYDOS | Design & Analysis Approaches to Evaluate Cardiovas...2012-05-30 EUGM | GAYDOS | Design & Analysis Approaches to Evaluate Cardiovas...
2012-05-30 EUGM | GAYDOS | Design & Analysis Approaches to Evaluate Cardiovas...
 
2014-10-22 EUGM | ROYCHAUDHURI | Phase I Combination Trials
2014-10-22 EUGM | ROYCHAUDHURI | Phase I Combination Trials2014-10-22 EUGM | ROYCHAUDHURI | Phase I Combination Trials
2014-10-22 EUGM | ROYCHAUDHURI | Phase I Combination Trials
 
Clinical Proof of Concept (PoC)
Clinical Proof of Concept (PoC)Clinical Proof of Concept (PoC)
Clinical Proof of Concept (PoC)
 
MPTI Talk
MPTI TalkMPTI Talk
MPTI Talk
 
Adaptive Phase 2 Design in Post Surgical Pain
Adaptive Phase 2 Design in Post Surgical PainAdaptive Phase 2 Design in Post Surgical Pain
Adaptive Phase 2 Design in Post Surgical Pain
 

Dernier

Control of Local Blood Flow: acute and chronic
Control of Local Blood Flow: acute and chronicControl of Local Blood Flow: acute and chronic
Control of Local Blood Flow: acute and chronic
MedicoseAcademics
 
👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...
👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...
👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...
Sheetaleventcompany
 
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Sheetaleventcompany
 
Dehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service Dehradun
Dehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service DehradunDehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service Dehradun
Dehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service Dehradun
Sheetaleventcompany
 
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
Sheetaleventcompany
 
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Sheetaleventcompany
 
💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...
💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...
💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...
Sheetaleventcompany
 
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
Sheetaleventcompany
 
Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...
Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...
Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...
dishamehta3332
 
Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...
Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...
Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...
Sheetaleventcompany
 

Dernier (20)

Call Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service Available
Call Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service AvailableCall Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service Available
Call Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service Available
 
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
 
Control of Local Blood Flow: acute and chronic
Control of Local Blood Flow: acute and chronicControl of Local Blood Flow: acute and chronic
Control of Local Blood Flow: acute and chronic
 
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
 
👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...
👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...
👉Chandigarh Call Girl Service📲Niamh 8868886958 📲Book 24hours Now📲👉Sexy Call G...
 
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
 
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
 
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
 
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdfShazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
 
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
 
Dehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service Dehradun
Dehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service DehradunDehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service Dehradun
Dehradun Call Girl Service ❤️🍑 8854095900 👄🫦Independent Escort Service Dehradun
 
Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...
Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...
Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...
 
Intramuscular & Intravenous Injection.pptx
Intramuscular & Intravenous Injection.pptxIntramuscular & Intravenous Injection.pptx
Intramuscular & Intravenous Injection.pptx
 
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
 
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
 
💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...
💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...
💚Chandigarh Call Girls 💯Riya 📲🔝8868886958🔝Call Girls In Chandigarh No💰Advance...
 
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
 
Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...
Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...
Whitefield { Call Girl in Bangalore ₹7.5k Pick Up & Drop With Cash Payment 63...
 
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
 
Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...
Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...
Jaipur Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Jaipur No💰...
 

2014-10-22 EUGM | PROSCHAN | Blinded Adaptations Permutations Tests and T-Tests

  • 2. IntroductionIntroduction • Joint work with Ekkehard Glimm and MartinJoint work with Ekkehard Glimm and Martin  Posch 2014, Stat. in Med. online  • See also Posch & Proschan 2012, Stat. in Med.  31 4146 415331, 4146‐4153
  • 3. IntroductionIntroduction • Clinical trials are pre‐meditated!Clinical trials are pre meditated! • We pre‐specify everything S i it / i f i it– Superiority/noninferiority – Population (inclusion/exclusion criteria) – Primary endpoint – Secondary endpoints – Analysis methods – Sample size/power
  • 4. IntroductionIntroduction • Changes made after seeing data are rightlyChanges made after seeing data are rightly  questioned: are investigators trying to get an  unfair advantage? – Changing primary endpoint because another  endpoint has a bigger treatment effect – Increasing sample size because the p‐value is close – Changing primary analysis because “assumptions  are violated”are violated – Changing population because of promising  subgroup resultssubgroup results
  • 5. IntroductionIntroduction • What’s the harm? 0 05 is arbitrary anywayWhat s the harm?  0.05 is arbitrary anyway • Problem: if unlimited freedom to change  anything the real error rate could be hugeanything, the real error rate could be huge • Reminiscent of Bible code controversy – Clairvoyant messages such as “Bin Laden” and  “twin towers” by skipping letters in Old Testament – Similar messages can be found by skipping letters  in any large book (Brendan McKay)
  • 6. IntroductionIntroduction • But changes made before unblinding areBut changes made before unblinding are  different • Under strong null hypothesis that treatment• Under strong null hypothesis that treatment  has NO effect, blinded data give no info about  treatment effecttreatment effect – Impossible to cheat even if it seems like cheating E if bli d d d t h bi d l di t ib ti it• E.g., even if blinded data show bimodal distribution, it  is not caused by treatment if strong null is true 
  • 7. Permutation TestsPermutation Tests • Permutation tests condition on all data otherPermutation tests condition on all data other  than treatment labels • Under strong null (D Z ) are independent• Under strong null, (D,Z ) are independent,  where Z are ±1 treatment indicators & D are  datadata  – Observed data D would have been observed  regardless of the treatment givenregardless of the treatment given – It is as if we observed D FIRST, then made the  treatment assignments Ztreatment assignments Z
  • 8. Permutation TestsPermutation Tests • Peaking at data changes nothing becausePeaking at data changes nothing because  permutation tests already condition on D • Conditional distribution of test statistic T(Z Y)• Conditional distribution of test statistic T(Z,Y)  given D is that of T(Z,y) where y is fixed Di ib i f Z d d d i i• Distribution of Z depends on randomization  method  – Simple – Permuted block, etc.
  • 9. Permutation TestsPermutation Tests T T C C C T C T C C T T C T T C 4 8 4 0 1 3 0 4 4 0 2 5 0 2 1 0 T-C T-C T-C T-C O ll T C 4.0 3.0 1.5 1.5 Overall T-C 2.5
  • 10. Permutation TestsPermutation Tests T C C T C T C T T T C C C T C T 4 8 4 0 1 3 0 4 4 0 2 5 0 2 1 0 T-C T-C T-C T-C O ll T C -4.0 3.0 -1.5 0.5 Overall T-C -0.5
  • 12. Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures • Blinded 2‐stage adaptive procedures use 1stBlinded 2 stage adaptive procedures use 1st   stage to make design changes – Sample size (Gould, 1992, Stat. in Med. 11, 55‐66; p ( , , , ; Gould & Shih, 1992 Commun. in Stat. 21, 2833‐ 2853)  P i d i ( di li li– Primary endpoint (e.g., diastolic versus systolic  blood pressure) • Previous argument shows that if adaptation is• Previous argument shows that if adaptation is  made before unblinding, a permutation test  on 1st stage data is still validon 1st stage data is still valid
  • 13. Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures • Careful! Subtle errors are possibleCareful!  Subtle errors are possible • E.g., in adaptive regression, which of the  following is (are) valid?following is (are) valid? 1. From ANCOVAs Y=β01+βz+βixi, i=1,…,k, pick xi that minimizes MSE; do permutation test onthat minimizes MSE; do permutation test on  winner 2 From ANCOVAs Y=β 1+β x i=1 k pick x that2. From ANCOVAs Y=β01+βixi, i=1,…,k, pick xi that  minimizes MSE; do permutation test on  Y=β01+βz+β*x*, where x* is winnerβ0 β β ,
  • 14. Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures • Careful! Subtle errors are possibleCareful!  Subtle errors are possible • E.g., in adaptive regression, which of the  following is (are) valid?following is (are) valid? 1. From ANCOVAs Y=β01+βz+βixi, i=1,…,k, pick xi that minimizes MSE; do permutation test onthat minimizes MSE; do permutation test on  winner 2 From ANCOVAs Y=β 1+β x i=1 k pick x that2. From ANCOVAs Y=β01+βixi, i=1,…,k, pick xi that  minimizes MSE; do permutation test on  Y=β01+βz+β*x*, where x* is winnerβ0 β β ,
  • 15. Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures • Unblinding and apparent α‐inflation also possible U b d g a d appa e t α at o a so poss b e if strong null is false • E.g., change primary endpoint based on “blinded” g g p y p data (X,Y1,Y2), Y1 and Y2 are potential primaries  and X=level of study drug in blood – X completely unblinds – Can then pick Y1 or Y2 with biggest z‐score Clearly inflates α– Clearly inflates α – Problem: strong null requires no effect on ANY variable examined (including X=level of study drug)
  • 16. Blinded 2‐Stage ProceduresBlinded 2 Stage Procedures • Claim: the following procedure is validClaim: the following procedure is valid – After viewing 1st stage data D1, choose test  statistic T1(Y1 Z1) and second stage data to collectstatistic T1(Y1,Z1) and second stage data to collect – After observing D2, choose T2(Y2,Z2) and method  of combining T1 and T2, f(T1,T2)of combining T1 and T2, f(T1,T2) – Conditional distribution of f(T1,T2) given (D1,D2) is  its stratified permutation distributionp – Stratified permutation test controls conditional, &  therefore unconditional type I error rate 
  • 17. Focus of Rest of TalkFocus of Rest of Talk • Permutation tests are asymptoticallyPermutation tests are asymptotically  equivalent to t‐tests • Suggests that adaptive t tests might be valid if• Suggests that adaptive t‐tests might be valid if  adaptive permutation tests are W id i b• We consider connections between  permutation and t‐tests, and validity of  d i f d i iadaptive t‐tests from adaptive permutation  tests 
  • 18. One‐Sample CaseOne Sample Case • Community randomized trials sometimes pair Co u ty a do ed t a s so et es pa match & randomize within pairs • E.g., COMMIT trial used community intervention g y to help people quit smoking—11 matched pairs • D=difference in quit rates between treatment (T)  & control (C) T C           D=T‐C Pair i         0.30     0.25        +0.05
  • 19. One‐Sample CaseOne Sample Case • Community randomized trials sometimes pair Co u ty a do ed t a s so et es pa match & randomize within pairs • E.g., COMMIT trial used community intervention g y to help people quit smoking—11 matched pairs • D=difference in quit rates between treatment (T)  & control (C) C T  D=T‐C Pair i         0.30     0.25        ‐0.05
  • 20. One‐Sample CaseOne Sample Case • Permuting labels changes only sign of DPermuting labels changes only sign of D • Permutation test conditions on |Di|= di +;  d + d d + ll lik l‐di + and di + are equally likely • The permutation distribution of Di is dist. ofThe permutation distribution of Di is dist. of 21w p1where /ZdZ   21w.p.1 21w.p.1where, / /ZdZ iii  
  • 21. One‐Sample CaseOne Sample Case • In 1st stage, adapt based on |D1|,…,|Dn| (blinded)g , p | 1|, ,| n| ( ) – E.g., increase stage 2  sample size because |Di| is very  large • What is conditional distribution of 1st stage sum• What is conditional distribution of  1st stage sum  ΣDi given |D1|=d1 +,…,|Dn|= dn + and the  adaptation?adaptation? – The adaptation is a function of |D1|,…,|Dn|  – The null distribution of ΣDi given |D1|=d1 +,…,|Dn|= dn + i g | 1| 1 , ,| n| n IS its permutation distribution – Conclusion: permutation test on stage 1 data still valid
  • 22. One‐Sample CaseOne Sample Case • Mean and variance of permutationMean and variance of permutation  distribution are      0)(E iiii ZEddZ       222 )(var )( iiiii iiii dZEddZ
  • 23. One‐Sample CaseOne Sample Case • Asymptotically, permutation distribution is sy ptot ca y, pe utat o d st but o s normal with this mean and variance (Lindeberg‐ Feller CLT) • I.e., conditional distribution of Di given , i g |D1|=d1 +,…,|Dn|= dn + is asymptotically N(0,di 2) • Depends on |D1|=d1 +,…,|Dn|= dn + only through  L2=di 2L di
  • 24. One‐Sample CaseOne Sample Case • Asymptotically, permutation distribution ofAsymptotically, permutation distribution of    N d dN D D T ii 2 2 2 )1,0( ,0 '      LD dD ii 2   n L Dns ns D T i i 2 22 02 0 )/1(;'   • Like t‐test with variance estimate s0 2 instead  of usual sample variance s2
  • 25. One‐Sample CaseOne Sample Case • Recap: Permutation distribution of T’ is dist ofRecap: Permutation distribution of T is dist of    12 |||,...,|given' n i DD D D T   2 i' i DT D    22 2 d dtd ')10( given' i DLN DT • Conclusion: T’ is asymptotically indep of L2   22 ondependtdoesn')1,0( iDLN
  • 26. One‐Sample CaseOne Sample Case • Begs question, is this true for all sample sizesBegs question, is this true for all sample sizes  under normality assumption? • if Di are iid N(0,2), then canif Di are iid N(0, ), then can ?fti d db' 2  i D D T ?oftindependenbe' 2 2    i i i D D T • Seems crazy, but it’s true!
  • 27. One‐Sample CaseOne Sample Case • One way to see that T’ is independent of Di 2One way to see that T is independent of Di uses Basu’s theorem:  • Recall S is sufficient for θ if F(y|s) does not  d d θ i i l if { ( )} f ll θdepend on θ; it is complete if E{g(S)}=0 for all θ implies g(S)≡0 with probability 1 • A is ancillary if its distribution does not depend• A is ancillary if its distribution does not depend  on θ • Basu, 1955, Sankhya 15, 377‐380: If S is a complete, sufficient statistic and A  is ancillary, then S and A are independent
  • 28. One‐Sample CaseOne Sample Case • Consider Di iid N(0 2) with 2 unknownConsider Di iid N(0, ) with  unknown –Di 2 is complete and sufficient – T’= Di/(Di 2)1/2 is ancillary because it is scale‐ invariant – By Basu’s theorem, T’ and Di 2 are independent
  • 29. One‐Sample CaseOne Sample Case • Same argument shows that the usual t‐Same argument shows that the usual t statistic is independent of Di 2 2 2• Under Di iid N(0,2) with 2 unknown –Di 2 is complete and sufficient – Usual t‐statistic T= Di/(ns2)1/2 is ancillary – By Basu’s theorem T and D 2 are independent– By Basu s theorem, T and Di are independent  ( Shao (2003): Mathematical Statistics, Springer) 
  • 30. One‐Sample CaseOne Sample Case • This result is important for adaptive sample sizeThis result is important for adaptive sample size  calculations – Stage 1 with n1= half of original sample size: changeStage 1 with n1  half of original sample size: change  second stage sample size to n2=n2(ΣDi 2) – Conditioned on ΣD 2:– Conditioned on ΣDi :  • Test statistic T1 has exact t‐distribution with n1‐1 d.f. • Test statistic T2 has exact t‐distribution with n2‐1 d.f. and is 2 2 independent of T1 • P‐values P1 and P2 are independent U(0,1) • Y={n 1/2Φ‐1(P )+n 1/2Φ‐1(P )}/(n +n )1/2 is N(0 1) under H• Y={n1 1/2Φ 1(P1)+n2 1/2Φ 1(P2)}/(n1+n2)1/2 is N(0,1) under H0
  • 31. One‐Sample CaseOne Sample Case • Reject if Y>zReject if Y>zα • Conditioned on ΣDi 2, type I error rate is α • Unconditional type I error rate is α as well • Most other two‐stage procedures are onlyMost other two stage procedures are only  approximate
  • 32. One‐Sample CaseOne Sample Case • Could even make other adaptations like changing p g g primary endpoint • Look at ΣDi 2 for each endpoint and determine  which one is primary    2– E.g., pick endpoint with smallest Di 2 • Slight generalization of our result shows that• Slight generalization of our result shows that  conditional distribution of T given adaptation is  still exact t 
  • 33. One‐Sample CaseOne Sample Case • Shows that conditional type I error rate givenShows that conditional type I error rate given  adaptation is controlled at level α • Unconditional type I error rate must also be• Unconditional type I error rate must also be  controlled at level α D i i l i i li• Derivation assumes multivariate normality  with variance/covariance not depending on  mean
  • 34. Two‐Sample CaseTwo Sample Case • Can use same reasoning in 2‐sample setting Ca use sa e easo g sa p e sett g • With equal sample sizes, the numerator is  YZYY • Permutation distribution is distribution of   ii C i T i YZYY Permutation distribution is distribution of    0,1each, iiii ZZyZ • Let sL 2 be “lumped” variance of all data  (treatment and control)(treatment and control) 
  • 35. Two‐Sample CaseTwo Sample Case • Mean and variance of permutation distribution p are   0)(EE iiii ZyyZ     22 )( 1 1 var Lii syy n yZ          • Basu’s theorem shows usual 2‐sample T is  independent of sL 2 under null hypothesis ofindependent of sL under null hypothesis of  common mean • Conditional distribution of T given sL 2 is still t
  • 36. Two‐Sample CaseTwo Sample Case • Two‐stage procedureTwo stage procedure – Stage 1: look at lumped variance and change stage  2 sample size – Conditioned on 1st stage lumped variance & H0 • T1 has t‐distribution with n1‐2 d.f. • T2 has t‐distribution with n2‐2 d.f. & independent of T1 • P‐values P1 and P2 are independent uniforms • {n1 1/2Φ‐1(P1)+n2 1/2Φ‐1(P2)}/(n1+n2)1/2 is N(0 1) under H0{n1 Φ (P1)+n2 Φ (P2)}/(n1+n2) is N(0,1) under H0 – Controls type I error rate conditionally and  unconditionally
  • 37. SummarySummary • Permutation tests are often valid even inPermutation tests are often valid even in  adaptive settings if blind is maintained • There is a close connection between• There is a close connection between  permutation tests and t‐tests C d d lidi f d i f• Can deduce validity of adaptive t‐tests from  validity of adaptive permutation tests